About us · Deep tech

The team bringing bioinspired biointerfaces to patients

Tirecat Health is a deep-tech spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Spanish National Research Council (CSIC), founded in 2024 in Barcelona.

Our team

The people behind RESKIN

Materials science, clinical practice, manufacturing and regulatory affairs, working together to take RESKIN to the clinic.

Co-founders

Dr. Salvio Suárez-García

Co-founder & CTO

Dr. Salvio Suárez-García

PhD in Materials Science (UAB, 2019, cum laude and Extraordinary Doctorate Award). Senior Researcher in the NANOSFUN group at ICN2 and inventor of the technology behind RESKIN. Research stays at the University of British Columbia, the Medical University of Vienna, LCC-CNRS Toulouse, Kiel University and the Waterloo Institute for Nanotechnology. Leads technology development, regulatory strategy and funding.

Prof. Daniel Ruiz-Molina

Co-founder & CSO

Prof. Daniel Ruiz-Molina

CSIC Professor and leader since 2005 of the NANOSFUN group at ICN2, where the bioinspired catechol chemistry behind RESKIN was developed. He has supervised more than 20 PhD theses and transferred several patented technologies to industry. In 2026 he led the candidacy that won the Duran Farell Award for Technological Innovation. Leads the scientific direction of Tirecat Health.

Team

Dr. Judit Ruiz Calbet

Clinical Expert

Dr. Judit Ruiz Calbet, MD

Medical doctor. Leads the clinical strategy and the coordination of clinical studies. Our link with clinicians.

Dr. José D. Bolaños

Product Developer

Dr. José D. Bolaños

Postdoctoral researcher at ICN2 (NANOSFUN). Leads synthesis scale-up, transfer to manufacturing and antimicrobial validation.

Dr. Verónica Arévalo

Regulatory & Business Development

Dr. Verónica Arévalo

“la Caixa” Foundation fellow: her Health Innovation Fellowship funds her incorporation into Tirecat Health. Leads the regulatory technical file, funding and partnerships.

Our story

From public research to a company

2010s

Born in NANOSFUN

More than ten years of research on bioinspired catechol chemistry at ICN2-CSIC.

2021

Patent filed

WO2022258780A1, owned by ICN2 and CSIC, with national phases in 8 jurisdictions.

2024

Tirecat Health is founded

Exclusive worldwide licence and selection by CaixaImpulse Innovation.

2026

CSIC joins

ICN2, CSIC and Criteria Capital Risc are shareholders, alongside the founders.

ICN2 – Catalan Institute of Nanoscience and Nanotechnology
CSIC – Consejo Superior de Investigaciones Científicas

Our purpose

“To fight chronic and fatal diseases by improving the quality of life of life-long patients.”

Our mission: to develop, manufacture and distribute bioinspired adhesive membranes, biointerfaces that revolutionise regenerative medicine worldwide.

Clinical and research network

Built with clinicians from day one

We have interviewed 35 clinicians in chronic wounds, infectious diseases and surgery across Spain and Italy, and we work with leading hospitals and research centres to design our first clinical study and future indications.

Our development is supported by specialised regulatory, preclinical (GLP) and manufacturing (ISO 13485) partners.

Funding and recognition

Backed by competitive programmes

2019–22

AGAUR Llavor and Innovadors grants and ICN2 seed and valorisation funds

2021

Barcelona Activa – Best high-tech business project

2022

Proof of Concept – Spanish Ministry of Science (NextGenerationEU)

2024

CaixaImpulse Innovation – “la Caixa” Foundation

2025

Transfiere – Deep Tech Start-ups Award

2025

Selected for the “la Caixa” Biotech Investor Forum

2026

Health Innovation Fellowships – “la Caixa” Foundation

2026

Duran Farell Award for Technological Innovation (NANOSFUN group)

“la Caixa” Foundation

Join us

Grow with Tirecat Health

Internships

Master’s and final-year students who want to learn how a deep-tech company takes a medical device to the clinic.

Research collaborations

Groups and clinicians who want to work with us on new indications of our bioinspired platform.

Get in touch

Partners, investors or press: we would like to hear from you.